Advertisement

Influence of androgen levels on conception probability in patients undergoing fertility treatment: a retrospective cohort study

  • Sebastian FindekleeEmail author
  • Panagiotis Sklavounos
  • Lisa Stotz
  • Romina M. Sima
  • Iulian Iordache
  • Carolin Spüntrup
  • Mariz Kasoha
  • Fabinshy Thangarajah
  • Erich-Franz Solomayer
  • Julia C. Radosa
Gynecologic Endocrinology and Reproductive Medicine
  • 7 Downloads

Abstract

Purpose

Primary and secondary sterility have become an issue of increasing importance due to demographic and social changes in society. Data regarding the association between female androgen levels and the probability of successful conception after fertility treatment are sparse and contradictive. This study was designed to assess this clinical question.

Methods

In this retrospective single-center cohort study concentrations of androgens androstenedione, dehydroepiandrosteronsulfat (DHEAS) and testosterone (ng/ml) were investigated in the serum of patients presenting for sterility at the department of reproductive medicine of Saarland University hospital Homburg between January 2015 and December 2017. Androgen levels were correlated with reproductive outcomes. Statistical analysis was performed with the aid of SPSS version 24. Significance for conception rates in dependence of androgen concentration was assessed using Kruskal–Wallis test (significance was estimated with p < 0.05).

Results

The laboratory values of a total of 301 patients were examined (64% primary, 36% secondary sterility). Median age at first visit at the fertility department was 32.7 years (range 20–47 years). 64 pregnancies were observed during the study period (conception rate 21.3%). 23 out of 301 patients (7.6%) suffered from hypoandrogenaemia, 248 (82.4%) had normal androgen levels and 30 (10%) showed hyperandrogenaemia (p = 0.25). Regarding patients in whom fertility treatment was successful 3 (4.7%) showed hypoandrogenaemia, 54 (84.4%) were normoandrogenaemic and 7 (10.9%) had hyperandrogenaemia (p = 0.40 Kruskal–Wallis test).

Conclusions

We found no association between female androgen levels and sterility and reproductive outcomes.

Keywords

Sterility Fertility treatment Conception rates Hyperandrogenaemia Hypoandrogenaemia 

Notes

Author contributions

SF: preparation of the manuscript, data analysis, and literature review. PS: layout. LS: statistics. RMS: statistics. II: figure. CS: tables. MK: literatur review. FT: statistics and development of the concept. EFS: counseling and proof of content. JCR: preparation of the manuscript, data analysis, and literature review.

Compliance with ethical standards

Conflict of interest

We declare that we have no conflict of interest.

Ethical approval

The study was conducted in concordance to the ethical standards of the institution.

Informed consent

As this was a retrospective study including only laboratory parameters no informed consent was obtained.

References

  1. 1.
    Sexty RE, Hamadneh J, Rösner S et al (2016) Cross-cultural comparison of fertility specific quality of life in German, Hungarian and Jordanian couples attending a fertility center. Health Qual Life Outcomes 14:27CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Diamond MP, Legro RS, Coutifaris C et al (2017) Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility. Am J Obstet Gynecol 217(2):191CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Seminar: polycystic ovary syndrome. Lancet 370:685–697CrossRefGoogle Scholar
  4. 4.
    Hossein Rashidi B, Hormoz B, Shahrokh Theraninejad E, Shariat M, Mahdavi A (2009) Testosterone and dehydroepiandrosterone sulphate levels and IVF/ICSI results. Gynecol Endocrinol 25(3):194–198CrossRefGoogle Scholar
  5. 5.
    Göretzlehner G, Lauritzen C (1990) Praktische Gynäkologie, 1st edn. de Gruyter, BerlinGoogle Scholar
  6. 6.
    Sunkara SK, Coomarasamy A (2011) Androgen pretreatment in poor responders undergoing controlled ovarian stimulation and in vitro fertilization treatment. Fertil Steril 95(8):e73–e74CrossRefGoogle Scholar
  7. 7.
    Cunningham P (2017) Pathophysiology, diagnosis and treatment of polycystic ovary syndrome. Nurs Stand 31(39):44–51CrossRefGoogle Scholar
  8. 8.
    Gleicher N, McCulloh DH, Kushnir VA et al (2015) Is there an androgen level threshold for aneuploidy risk in infertile women? Reprod Biol Endocrinol 6(13):38CrossRefGoogle Scholar
  9. 9.
    Shirazi TN, Bossio JA, Puts DA, Chivers ML (2018) Menstrual cycle phase predicts women’s hormonal responses to sexual stimuli. Horm Behav 103:45–53CrossRefGoogle Scholar
  10. 10.
    Narkwichean A, Maalouf W, Campbell BK, Jayaprakasan K (2013) Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. Reprod Biol Endocrinol 11:44CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Triantafyllidou O, Sigalos G, Vlahos N (2017) Dehydroepiandrosterone (DHEA) supplementation and IVF outcome in poor responders. Hum Fertil (Camb) 20(2):80–87CrossRefGoogle Scholar
  12. 12.
    Kim CH (2013) Androgen supplementation in IVF. Minerva Ginecol 65(5):497–504Google Scholar
  13. 13.
    Nagels HE, Rishworth JR, Siristatidis CS, Kroon B (2015) Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev 26(11):CD009749Google Scholar
  14. 14.
    Qin JC, Fan L, Qin AP (2016) The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. J Gynecol Obstet Biol Reprod (Paris) 46(1):1–7Google Scholar
  15. 15.
    Wierman ME, Arlt W, Basson R (2014) Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99(10):3489–3510CrossRefGoogle Scholar
  16. 16.
    Yilmaz SA, Kebapcilar A, Koplay M, Kerimoglu OS, Pekin AT, Gencoglu B, Dogan NU, Celik C (2015) Association of clinical androgen excess with radial artery intima media thickness in women with polycystic ovary syndrome. Gynecol Endocrinol 31(6):477–482CrossRefGoogle Scholar
  17. 17.
    Lasley BL, Santoro N, Randolf JF, Gold EB, Crawford S, Weiss G, McConnell DS, Sowers MF (2002) The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab. 87(8):3760–3767CrossRefGoogle Scholar
  18. 18.
    Yeung TW, Chai J, Li RH, Lee VC, Ho PC, Ng EH (2014) A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil Steril 102(1):108–115CrossRefGoogle Scholar
  19. 19.
    Ubaldi FM, Rienzi L, Ferrero S, Baroni E, Sapienza F, Cobellis L, Greco E (2005) Management of poor responders in IVF. Reprod Biomed Online 10(2):235–246CrossRefGoogle Scholar
  20. 20.
    Surrey ES, Schoolcraft WB (2000) Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril 73(4):667–676CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Sebastian Findeklee
    • 1
    Email author
  • Panagiotis Sklavounos
    • 1
  • Lisa Stotz
    • 1
  • Romina M. Sima
    • 1
    • 2
    • 3
  • Iulian Iordache
    • 1
  • Carolin Spüntrup
    • 1
  • Mariz Kasoha
    • 1
  • Fabinshy Thangarajah
    • 4
  • Erich-Franz Solomayer
    • 1
  • Julia C. Radosa
    • 1
  1. 1.Klinik für Frauenheilkunde, Geburtshilfe und ReproduktionsmedizinUniversitätsklinikum des SaarlandesHomburgGermany
  2. 2.UMF Carol DavilaBucharestRomania
  3. 3.St. John Hospital, Bucur MaternityBucharestRomania
  4. 4.Department of Obstetrics and Gynecology, Medical FacultyUniversity of CologneCologneGermany

Personalised recommendations